Tibet Rhodiola Pharmaceutical Holding Co - Asset Resilience Ratio

Latest as of March 2026: 15.57%

Tibet Rhodiola Pharmaceutical Holding Co (600211) has an Asset Resilience Ratio of 15.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥995.32 Million
≈ $145.65 Million USD Cash + Short-term Investments

Total Assets

CN¥6.39 Billion
≈ $935.32 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2025)

This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Asset Resilience Ratio has changed over time. Check how strategically is Tibet Rhodiola Pharmaceutical Holding Co's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600211 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥995.32 Million 15.57%
Total Liquid Assets CN¥995.32 Million 15.57%

Asset Resilience Insights

  • Good Liquidity Position: Tibet Rhodiola Pharmaceutical Holding Co maintains a healthy 15.57% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Tibet Rhodiola Pharmaceutical Holding Co Industry Peers by Asset Resilience Ratio

Compare Tibet Rhodiola Pharmaceutical Holding Co's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Tibet Rhodiola Pharmaceutical Holding Co (2002–2025)

The table below shows the annual Asset Resilience Ratio data for Tibet Rhodiola Pharmaceutical Holding Co.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 28.45% CN¥1.78 Billion
≈ $260.89 Million
CN¥6.27 Billion
≈ $917.12 Million
+7.87pp
2024-12-31 20.57% CN¥976.62 Million
≈ $142.91 Million
CN¥4.75 Billion
≈ $694.68 Million
+9.34pp
2023-12-31 11.23% CN¥515.34 Million
≈ $75.41 Million
CN¥4.59 Billion
≈ $671.27 Million
-8.10pp
2022-12-31 19.33% CN¥792.49 Million
≈ $115.97 Million
CN¥4.10 Billion
≈ $599.87 Million
+5.19pp
2021-12-31 14.14% CN¥537.87 Million
≈ $78.71 Million
CN¥3.80 Billion
≈ $556.45 Million
+13.64pp
2020-12-31 0.51% CN¥14.96 Million
≈ $2.19 Million
CN¥2.94 Billion
≈ $430.84 Million
-2.74pp
2019-12-31 3.25% CN¥90.00 Million
≈ $13.17 Million
CN¥2.77 Billion
≈ $404.93 Million
+0.41pp
2016-12-31 2.84% CN¥65.00 Million
≈ $9.51 Million
CN¥2.29 Billion
≈ $335.20 Million
+2.80pp
2010-12-31 0.04% CN¥308.80K
≈ $45.19K
CN¥735.47 Million
≈ $107.62 Million
-0.05pp
2009-12-31 0.10% CN¥709.60K
≈ $103.84K
CN¥743.70 Million
≈ $108.83 Million
+0.08pp
2008-12-31 0.01% CN¥112.40K
≈ $16.45K
CN¥829.66 Million
≈ $121.41 Million
-0.03pp
2007-12-31 0.04% CN¥339.80K
≈ $49.72K
CN¥831.96 Million
≈ $121.74 Million
+0.01pp
2006-12-31 0.03% CN¥252.00K
≈ $36.88K
CN¥866.90 Million
≈ $126.86 Million
+0.02pp
2005-12-31 0.01% CN¥114.60K
≈ $16.77K
CN¥820.62 Million
≈ $120.08 Million
-0.46pp
2004-12-31 0.48% CN¥3.69 Million
≈ $540.55K
CN¥777.25 Million
≈ $113.74 Million
-0.03pp
2003-12-31 0.51% CN¥3.81 Million
≈ $557.96K
CN¥754.36 Million
≈ $110.39 Million
+0.05pp
2002-12-31 0.46% CN¥3.37 Million
≈ $492.55K
CN¥733.08 Million
≈ $107.27 Million
--
pp = percentage points

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.79 Billion
CN¥12.22 Billion CNY
Market Cap Rank
#6537 Global
#1323 in China
Share Price
CN¥37.91
Change (1 day)
-1.79%
52-Week Range
CN¥35.31 - CN¥56.43
All Time High
CN¥165.99
About

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more